Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma

被引：0
|
作者：
Esteban-Fabro, Roger [1 ]
Willoughby, Catherine E. [1 ]
Pique-Gili, Marta [1 ]
Peix, Judit [1 ]
Montironi, Carla [1 ]
Abril-Fornaguera, Jordi [1 ]
Torrens, Laura [1 ]
Pinyol, Roser [1 ]
Llovet, Josep M. [1 ,2 ,3 ]
机构：
[1] Liver Canc Translat Res Lab, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Liver Unit, Barcelona, Spain
[2] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, Tisch Canc Inst, New York, NY USA
[3] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AS053
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] CABOZANTINIB ENHANCES THE EFFICACY AND IMMUNE MODULATORY ACTIVITY OF ANTI-PD1 TREATMENT IN A SYNGENEIC MOUSE MODEL OF HCC
    Esteban-Fabro, Roger
    Willoughby, Catherine E.
    Pique-Gili, Marta
    Peix, Judit
    Abril-Fornaguera, Jordi
    Pinyol, Roser
    Llovet, Josep M.
    HEPATOLOGY, 2019, 70 : 1201A - 1202A
  • [2] Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
    Esteban-Fabro, Roger
    Willoughby, Catherine E.
    Pique-Gili, Marta
    Montironi, Carla
    Abril-Fornaguera, Jordi
    Peix, Judit
    Torrens, Laura
    Mesropian, Agavni
    Balaseviciute, Ugne
    Miro-Mur, Francesc
    Mazzaferro, Vincenzo
    Pinyol, Roser
    Llovet, Josep M.
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2449 - 2460
  • [3] Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
    Sparks, R.
    Rolland, S.
    Klinz, S.
    Meyer-Losic, F.
    Nakhle, J.
    Delille, R.
    de Boisferonc, M. Hillairet
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models
    Rolland, S.
    Klinz, S. G.
    Meyer-Losic, F.
    Nahkle, J.
    Delille, R.
    de Boisferon, M. Hillairet
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
    Wei, Yuhua
    Wang, Yufeng
    Liu, Nanbin
    Qi, Ran
    Xu, Yan
    Li, Kun
    Feng, Yu
    Shi, Baomin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [6] Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model
    Semba, Taro
    Tabata, Kimiyo
    Ozawa, Yoichi
    Miyano, Saori Watanabe
    Matsui, Junji
    Funahashi, Yasuhiro
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma
    Xiang, Xiaonan
    Wang, Kai
    Zhang, Hui
    Mou, Haibo
    Shi, Zhixiong
    Tao, Yaoye
    Song, Hongliang
    Lian, Zhengxing
    Wang, Shuai
    Lu, Di
    Wei, Xuyong
    Xie, Haiyang
    Zheng, Shusen
    Wang, Jianguo
    Xu, Xiao
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (11) : 1603 - 1620
  • [8] Combination with a novel STING agonist significantly improves efficacy of anti-PD1 therapy in mouse syngeneic tumor models
    Perera, Samanthi A.
    Kopinja, Johnny E.
    Ma, Yanhong
    Laskey, Jason
    Chakravarthy, Kalyan
    Cui, Long
    Chen, Yiping
    Presland, Jeremy
    Sharma, Sharad
    Zhao, Shuxia
    Piesvaux, Jennifer
    Minnihan, Ellen C.
    Ferguson, Heidi
    Woo, Hyun Chong
    Knemeyer, Ian
    Kariv, Ilona
    Tse, Archie
    Cemerski, Saso
    Cumming, Jared
    Trotter, B. Wesley
    Pan, Bo-Sheng
    Addona, George H.
    Long, Brian J.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [9] Auranofin enhances the efficacy of anti-PD1 immunotherapy
    Zhao, Zichen
    Hu, Shichuan
    Zhang, Yan
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Cabozantinib may enhance efficacy of anti-PD-1 therapy in hepatocellular carcinoma through suppression of MDSCs
    Ou, Da-Liang
    Lin, Li
    Hsu, Chia-Lang
    Jian, Cheng-Zhe
    Lee, Bin-Shyun
    Cheng, Ann-Lii
    Hsu, Chiun
    ANNALS OF ONCOLOGY, 2022, 33 : S483 - S483
12345